ARGXNasdaqManufacturing

Argenx SE

895.00

Closed17:59 ET

Open896.00Volume462,446Mkt cap$55.3BP/E42.46EPS21.08

Day893.85 – 910.927%52-wk661.85 – 1,072.7557%

ARGX

Argenx SE

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

News

23dargenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
23dargenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
24dHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

News

Next report

Last report

−1.61%

vs ±8.8% implied · ×0.18

shaded = implied · ▲▼ = realized

Oct 22 '26 · confirmed

History

Linked news

1dABBV · customerAbbVie posts Q3 net revenues $17.404 billion, diluted EPS $2.37, adjusted EPS $3.82
9dHALO · supplierHalozyme to Report Third Quarter 2026 Financial and Operating Results

News

Largest filed tie

13F top-10 QoQ

−3.08%

shares held · 10 largest managers

13F · Jun 30 '26123d lag

508 managers

Top fund weight

0.05%

ARGX weight · VT

N-PORTJul 31 '26

1 fund

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Who supplies Argenx, and who buys from it

Argenx has 1 disclosed supplier and 2 disclosed customers in SEC filings.

Supply chain

SEC EDGAREDGAR · Mar 19 '26

Sources

HALO

← Buys from

ARGX

ABBV

AgomAb Therapeuticsunlisted

Sells to →

Suppliers1Customers2

HALO

ARGX

ABBV

AgomAb Therapeuticsunlisted

suppliercustomerunlisted2°second-degree (Extended)Full map

Thick line = filed share ·Moves · 14:16 ETSources

Supply chain

SEC EDGAR

Sources for ARGX relationships

SEC EDGAR · verbatim disclosure

Sources for ARGX relationships

EDGAR · verbatim disclosure · 3Show sources· 3

supplier

HALOHalozyme Therapeutics

SentenceIn February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics, which was later amended in September 2020 and again in September 2024.

ARGX 20-Faccession 0001697862-26-000032filed Mar 19 '26HALO

customer

ABBVAbbVie

SentenceIn April 2016, the Company entered into the AbbVie Collaboration Agreement to develop and commercialize ARGX-115 (ABBV-151).

ARGX 20-Faccession 0001697862-26-000032filed Mar 19 '26ABBV

—AgomAb Therapeutics NVunlisted

SentenceIn March 2019, the Company entered into a license agreement with AgomAb Therapeutics NV for the use of HGF-mimetic SIMPLE Antibodies™, developed under the Company's Immunology Innovative Program. In exchange for granting this license, the Company received a profit share in AgomAb Therapeutics NV.

Order: filed share, then A–Z, unlisted last

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders

Dependency

Sources

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders